p.75 抽出テキスト

fibrillation: SNOozE-AF. Can J Cardiol 2019;35:1457–64. https://doi.org/10.1016/j.cjca. 2019.07.627 156. Traaen GM, Overland B, Aakeroy L, Hunt TE, Bendz C, Sande L, et al. Prevalence, risk factors, and type of sleep apnea in patients with paroxysmal atrial fibrillation. Int J Cardiol Heart Vasc 2020;26:100447. https://doi.org/10.1016/j.ijcha.2019.100447 157. Kadhim K, Middeldorp ME, Elliott AD, Agbaedeng T, Gallagher C, Malik V, et al. Prevalence and assessment of sleep-disordered breathing in patients with atrial fibrillation: a systematic review and meta-analysis. Can J Cardiol 2021;37:1846–56. https:// doi.org/10.1016/j.cjca.2021.09.026 158. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study. Eur Heart J 2012;33:1500–10. https://doi.org/10.1093/eurheartj/ ehr488 159. Lopes LC, Spencer FA, Neumann I, Ventresca M, Ebrahim S, Zhou Q, et al. Systematic review of observational studies assessing bleeding risk in patients with atrial fibrillation not using anticoagulants. PLoS One 2014;9:e88131. https://doi.org/10.1371/journal. pone.0088131 160. Potpara TS, Polovina MM, Licina MM, Marinkovic JM, Lip GY. Predictors and prognostic implications of incident heart failure following the first diagnosis of atrial fibrillation in patients with structurally normal hearts: the Belgrade atrial fibrillation study. Eur J Heart Fail 2013;15:415–24. https://doi.org/10.1093/eurjhf/hft004 161. Noubiap JJ, Feteh VF, Middeldorp ME, Fitzgerald JL, Thomas G, Kleinig T, et al. A meta-analysis of clinical risk factors for stroke in anticoagulant-naive patients with atrial fibrillation. Europace 2021;23:1528–38. https://doi.org/10.1093/europace/euab087 162. McEvoy JW, Touyz RM, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 2024. https://doi.org/10.1093/eurheartj/ehae178 163. Santoro F, Di Biase L, Trivedi C, Burkhardt JD, Paoletti Perini A, Sanchez J, et al. Impact of uncontrolled hypertension on atrial fibrillation ablation outcome. JACC Clin Electrophysiol 2015;1:164–73. https://doi.org/10.1016/j.jacep.2015.04.002 164. Trines SA, Stabile G, Arbelo E, Dagres N, Brugada J, Kautzner J, et al. Influence of risk factors in the ESC-EHRA EORP atrial fibrillation ablation long-term registry. Pacing Clin Electrophysiol 2019;42:1365–73. https://doi.org/10.1111/pace.13763 165. Shah AN, Mittal S, Sichrovsky TC, Cotiga D, Arshad A, Maleki K, et al. Long-term outcome following successful pulmonary vein isolation: pattern and prediction of very late recurrence. J Cardiovasc Electrophysiol 2008;19:661–7. https://doi.org/10.1111/j.1540- 8167.2008.01101.x 166. Berruezo A, Tamborero D, Mont L, Benito B, Tolosana JM, Sitges M, et al. Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. Eur Heart J 2007;28:836–41. https://doi.org/10.1093/eurheartj/ ehm027 167. Themistoclakis S, Schweikert RA, Saliba WI, Bonso A, Rossillo A, Bader G, et al. Clinical predictors and relationship between early and late atrial tachyarrhythmias after pulmonary vein antrum isolation. Heart Rhythm 2008;5:679–85. https://doi.org/10.1016/ j.hrthm.2008.01.031 168. Letsas KP, Weber R, Burkle G, Mihas CC, Minners J, Kalusche D, et al. Pre-ablative predictors of atrial fibrillation recurrence following pulmonary vein isolation: the potential role of inflammation. Europace 2009;11:158–63. https://doi.org/10.1093/europace/ eun309 169. Khaykin Y, Oosthuizen R, Zarnett L, Essebag V, Parkash R, Seabrook C, et al. Clinical predictors of arrhythmia recurrences following pulmonary vein antrum isolation for atrial fibrillation: predicting arrhythmia recurrence post-PVAI. J Cardiovasc Electrophysiol 2011;22:1206–14. https://doi.org/10.1111/j.1540-8167.2011.02108.x 170. Kamioka M, Hijioka N, Matsumoto Y, Nodera M, Kaneshiro T, Suzuki H, et al. Uncontrolled blood pressure affects atrial remodeling and adverse clinical outcome in paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 2018;41:402–10. https://doi. org/10.1111/pace.13311 171. Zylla MM, Hochadel M, Andresen D, Brachmann J, Eckardt L, Hoffmann E, et al. Ablation of atrial fibrillation in patients with hypertension—an analysis from the German ablation registry. J Clin Med 2020;9:1–14. https://doi.org/10.3390/jcm9082402 172. Galzerano D, Di Michele S, Paolisso G, Tuccillo B, Lama D, Carbotta S, et al. A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients. J Renin Angiotensin Aldosterone Syst 2012; 13:496–503. https://doi.org/10.1177/1470320312443909 173. Du H, Fan J, Ling Z, Woo K, Su L, Chen S, et al. Effect of nifedipine versus telmisartan on prevention of atrial fibrillation recurrence in hypertensive patients. Hypertension 2013; 61:786–92. https://doi.org/10.1161/HYPERTENSIONAHA.111.202309 174. Giannopoulos G, Kossyvakis C, Efremidis M, Katsivas A, Panagopoulou V, Doudoumis K, et al. Central sympathetic inhibition to reduce postablation atrial fibrillation recurrences in hypertensive patients: a randomized, controlled study. Circulation 2014;130: 1346–52. https://doi.org/10.1161/CIRCULATIONAHA.114.010999 175. Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010;55:2299–307. https://doi.org/10.1016/j.jacc.2010.01.043 176. Blum S, Aeschbacher S, Meyre P, Zwimpfer L, Reichlin T, Beer JH, et al. Incidence and predictors of atrial fibrillation progression. J Am Heart Assoc 2019;8:e012554. https:// doi.org/10.1161/JAHA.119.012554 177. Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we do? Eur Heart J 2015;36:3250–7. https://doi.org/10.1093/eurheartj/ehv513 178. Santhanakrishnan R, Wang N, Larson MG, Magnani JW, McManus DD, Lubitz SA, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 2016;133:484–92. https://doi.org/10.1161/CIRCULATIONAHA.115.018614 179. Rossello X, Gil V, Escoda R, Jacob J, Aguirre A, Martín-Sánchez FJ, et al. Editor’s choice – impact of identifying precipitating factors on 30-day mortality in acute heart failure patients. Eur Heart J Acute Cardiovasc Care 2019;8:667–80. https://doi.org/10.1177/ 2048872619869328 180. Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med 1998;158:1316–20. https://doi.org/10.1001/archinte.158.12.1316 181. Rohla M, Weiss TW, Pecen L, Patti G, Siller-Matula JM, Schnabel RB, et al. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events—European Registry in Atrial Fibrillation (PREFER in AF). BMJ Open 2019;9: e022478. https://doi.org/10.1136/bmjopen-2018-022478 182. Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GY. Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol 2016;203:660–6. https:// doi.org/10.1016/j.ijcard.2015.10.220 183. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023;44:3627–39. https://doi.org/10.1093/ eurheartj/ehad195 184. ACTIVE I Investigators; Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, et al. Irbesartan in patients with atrial fibrillation. N Engl J Med 2011;364:928–38. https:// doi.org/10.1056/NEJMoa1008816 185. Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ 2015;351:h4451. https://doi.org/10.1136/bmj.h4451 186. Groenveld HF, Crijns HJ, Van den Berg MP, Van Sonderen E, Alings AM, Tijssen JG, et al. The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J Am Coll Cardiol 2011;58:1795–803. https://doi.org/10.1016/j.jacc.2011.06. 055 187. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 2021;42:3427–520. https://doi.org/10.1093/eurheartj/ehab364 188. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 2016;37:455–62. https://doi.org/10. 1093/eurheartj/ehv464 189. Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, et al. Heart failure with midrange ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 2018;20:1230–9. https:// doi.org/10.1002/ejhf.1149 190. Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 2018;39:26–35. https://doi.org/10.1093/eurheartj/ehx564 191. Țica O, Khamboo W, Kotecha D. Breaking the cycle of heart failure with preserved ejection fraction and atrial fibrillation. Card Fail Rev 2022;8:e32. https://doi.org/10. 15420/cfr.2022.03 192. Nguyen BO, Crijns H, Tijssen JGP, Geelhoed B, Hobbelt AH, Hemels MEW, et al. Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial. Europace 2022; 24:910–20. https://doi.org/10.1093/europace/euab270 193. Wang A, Green JB, Halperin JL, Piccini JP, Sr. Atrial fibrillation and diabetes mellitus: JACC review topic of the week. J Am Coll Cardiol 2019;74:1107–15. https://doi.org/ 10.1016/j.jacc.2019.07.020 194. Alijla F, Buttia C, Reichlin T, Razvi S, Minder B, Wilhelm M, et al. Association of diabetes with atrial fibrillation types: a systematic review and meta-analysis. Cardiovasc Diabetol 2021;20:230. https://doi.org/10.1186/s12933-021-01423-2 195. Ding WY, Kotalczyk A, Boriani G, Marin F, Blomstrom-Lundqvist C, Potpara TS, et al. Impact of diabetes on the management and outcomes in atrial fibrillation: an analysis from the ESC-EHRA EORP-AF long-term general registry. Eur J Intern Med 2022; 103:41–9. https://doi.org/10.1016/j.ejim.2022.04.026 196. Proietti M, Romiti GF, Basili S. The case of diabetes mellitus and atrial fibrillation: underlining the importance of non-cardiovascular comorbidities. Eur J Intern Med 2022;103:38–40. https://doi.org/10.1016/j.ejim.2022.06.017 Downloaded from academic.oup.com/eurheartj/article/45/36/3314/7738779 by guest on 07 October 2026